OBJECTIVE: To determine the predictive value on survival of optic neuritis (ON) as onset manifestation of MS. METHODS: We used data obtained from the Danish Multiple Sclerosis Registry, which includes virtually all patients diagnosed with MS in Denmark. From 1949 to 1990, 7,548 unselected patients fulfilling standardized diagnostic criteria of MS were registered. RESULTS: The onset manifestation of MS was known in 6,923 patients, and was ON in 1,282 patients (19%). The mean age at onset was 31.1 years for these patients compared with 34.8 years for patients with another or unknown onset manifestation of MS (non-ON) (p < 0.001). The mean delay from the first known manifestation of MS to the final diagnosis of MS was 6.1 years (ON) and 4.2 years (non-ON). The median survival time from onset of ON was 30 years in men (compared with 41 years in the matched general male population) and 40 years in women (versus 47 years). The excess death rate increased with age at onset of MS in people of each sex. Excess death rate for women differed significantly between patients with ON as onset manifestation and patients with another or unknown onset manifestation of MS (8.3 versus 13.0). In patients with ON as onset manifestation of MS, the excess death rate was significantly higher in men (14.0) than in women (8.3). CONCLUSION: ON as onset manifestation of MS indicates a more favorable prognosis of survival of MS judged by excess death rate only in women.
OBJECTIVE: To determine the predictive value on survival of optic neuritis (ON) as onset manifestation of MS. METHODS: We used data obtained from the Danish Multiple Sclerosis Registry, which includes virtually all patients diagnosed with MS in Denmark. From 1949 to 1990, 7,548 unselected patients fulfilling standardized diagnostic criteria of MS were registered. RESULTS: The onset manifestation of MS was known in 6,923 patients, and was ON in 1,282 patients (19%). The mean age at onset was 31.1 years for these patients compared with 34.8 years for patients with another or unknown onset manifestation of MS (non-ON) (p < 0.001). The mean delay from the first known manifestation of MS to the final diagnosis of MS was 6.1 years (ON) and 4.2 years (non-ON). The median survival time from onset of ON was 30 years in men (compared with 41 years in the matched general male population) and 40 years in women (versus 47 years). The excess death rate increased with age at onset of MS in people of each sex. Excess death rate for women differed significantly between patients with ON as onset manifestation and patients with another or unknown onset manifestation of MS (8.3 versus 13.0). In patients with ON as onset manifestation of MS, the excess death rate was significantly higher in men (14.0) than in women (8.3). CONCLUSION: ON as onset manifestation of MS indicates a more favorable prognosis of survival of MS judged by excess death rate only in women.
Authors: Hormuzdiyar H Dasenbrock; Seth A Smith; Arzu Ozturk; Sheena K Farrell; Peter A Calabresi; Daniel S Reich Journal: J Neuroimaging Date: 2011-04 Impact factor: 2.486
Authors: Thomas Jenkins; Olga Ciccarelli; Ahmed Toosy; Katherine Miszkiel; Claudia Wheeler-Kingshott; Daniel Altmann; Laura Mancini; Steve Jones; Gordon Plant; David Miller; Alan Thompson Journal: Hum Brain Mapp Date: 2010-02 Impact factor: 5.038
Authors: Basanta Bhaduri; Ryan M Nolan; Ryan L Shelton; Lara A Pilutti; Robert W Motl; Stephen A Boppart Journal: J Biomed Opt Date: 2016-09-01 Impact factor: 3.170